MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, November 15, 2014

another Alemtuzumab Update: Lemtrada Finally Wins FDA Nod

By John Gever, Managing Editor, MedPage Today    - November 15, 2014

Overcoming an initial rejection by the FDA, alemtuzumab (Lemtrada) was given marketing approval late Friday for treatment of relapsing-remitting multiple sclerosis but "generally" as a third-line treatment, its manufacturer said.
The approval also comes with a requirement for a boxed warning about "serious, sometimes fatal autoimmune conditions," severe infusion reactions, and the possibility of increased risk of certain cancers, according to the announcement from Sanofi's Genzyme unit.
And alemtuzumab will only be available through a restricted distribution program that will require prescribers, pharmacies, and patients to be certified. The intent is to "educate healthcare providers and patients on the serious risks associated with Lemtrada and the appropriate periodic monitoring required to support the detection of these risks for 48 months after the last infusion," the statement said.
Alemtuzumab is unusual among MS drugs in several respects. It was sold for many years as Campath for treating certain leukemias. In MS, it is administered by IV infusion in two annual cycles, the first lasting 5 days and the second 3 days. Its target is the CD52 protein on the surfaces of T and B cells. The two treatment cycles temporarily deplete these cells. Their subsequent re-population is marked by a transformation in immune responsiveness, such that the autoimmune attack on myelin fibers in the nervous system is shut down or at least reduced in most patients.

 Keep CURRENT with MS Views and News - OPT-IN here


No comments: